Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study
- 18 June 2015
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 56 (12) , 3281-3287
Abstract
Rituximab® provides high response rates and effective disease palliation in patients with splenic marginal zone lymphoma (SMZL). We conducted a phase II trial in patients with SMZL who were either untreated or were splenectomized but had shown disease progression within 1 year after splenectomy. Treatment consisted of six courses of Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone (R-COMP). Fifty-one patients were eligible for the analysis. The overall response rate was 84%. The 6-year progression-free survival and overall survival were 54% and 72%, respectively. Toxicity was substantial (grade≥3 neutropenia: 26%; grade≥3 infections: 8%). Of the 15 deaths, two occurred on treatment (one sepsis and one pneumonia). Six deaths were due to lymphoma progression, four to secondary neoplasia, one to sepsis, one to pneumonia and one to splenectomy complications. R-COMP should be restricted to patients with bulky disease associated with symptoms or to patients with possible histological transformation.Keywords
This publication has 30 references indexed in Scilit:
- Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatmentLeukemia & Lymphoma, 2014
- High‐grade transformation in splenic marginal zone lymphoma with circulating villous lymphocytes: the site of transformation influences response to therapy and prognosisBritish Journal of Haematology, 2008
- Splenic marginal zone lymphoma: a prognostic model for clinical useBlood, 2006
- Splenic marginal zone lymphomaBlood Reviews, 2005
- Splenic marginal zone lymphoma with or without villous lymphocytesCancer, 2004
- Splenic marginal zone lymphomaBlood, 2003
- Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patientsBritish Journal of Haematology, 2003
- Splenic marginal-zone lymphoma: a distinct clinical and pathological entityThe Lancet Oncology, 2003
- Treatment of Splenic Marginal Zone B-Cell Lymphoma: An Analysis of 81 PatientsClinical Lymphoma, 2002
- Progression to Large B-Cell Lymphoma in Splenic Marginal Zone LymphomaAmerican Journal of Surgical Pathology, 2001